Stock News & Analysis

Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.

VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.

Warren Buffett has weathered many stock market crashes over his years of investing.

For those waiting for a Nike turnaround, it looks like there's more waiting ahead.

Looking past Walmart just because of its yield could be a mistake.

Nvidia and AMD are two great semiconductor stocks to buy and hold for the long term.

This nuclear company boasts a strong moat and should benefit from growing support for nuclear energy.

Peter Thiel has scored some big wins as a tech investor and company founder, but that doesn't mean everything he touches will turn to gold.

HPE stock soared last month on booming AI data center demand. Here's what drove the rally and why the enterprise computing giant's valuation still looks reasonable.

Don't get your hopes up.

Lockheed Martin owned fifth-generation fighter jets. The sixth generation, however, belongs to Boeing.

The EV maker's growth year looks nearly certain -- but is it enough to justify the stock's price?

Micron is seeing surging revenue and earnings growth.

Broadcom's revenue has nearly doubled since late 2024, while Intel's has stalled — a widening gap that raises questions about competitive positioning.

Netflix may be a market laggard lately, but that should not make you lose sight of the long-term opportunity.

Don't bank on a Nike comeback. Both its quarterly results and guidance were terrible.

MercadoLibre recently surpassed Coupang in quarterly revenue for the first time, marking a pivotal shift in their competitive positioning.

Bond yields are rising fast; the market looks expensive. A bear could be on the way. Consider buying Berkshire Hathaway, Realty Income, and Progressive.

A 27% cut in construction costs makes a solid sales pitch. But will it get the orders the stock already expects?

Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.